{
    "nct_id": "NCT05604560",
    "official_title": "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer",
    "inclusion_criteria": "* Ability to understand and willingness to sign a written informed consent document.\n* Age ≥18 years.\n* Newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas.\n* Tumor must be resectable.\n* Patient's acceptance to have a tumor biopsy.\n* ECOG performance status 0 or 1\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* For both Women and Men, must use acceptable form of birth control while on study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have received any anti-pancreatic cancer therapy.\n* Have been diagnosed with another malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study.\n* Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures\n* Subjects with active, known or suspected autoimmune disease that may relapse.\n* Systemic steroid therapy (> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.\n* Active infection requiring systemic therapy.\n* Infection with HIV or hepatitis B or C at screening•\n* History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Prior allogeneic stem cell transplantation or organ transplantation\n* Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.\n* Have received a live vaccine ≤ 28 days before first dose of study drug.\n* Use of QT prolonging drugs within 2 weeks before the start of SX-682 dosing and for the length of the study.\n* ECG demonstrating a QTc interval ≥ 470 msec or patients with congenital long QT syndrome.\n* Severe hypersensitivity reaction to any monoclonal antibody.\n* Concurrent participation in another therapeutic clinical study\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}